The Ledger

Addus HomeCare just made the healthcare sector’s biggest disclosed-price acquisition of the week, buying its way into six new states for personal care services at the exact moment private equity’s broader healthcare deal count is on pace for its lowest year since 2017. Addus HomeCare Corporation (Nasdaq: ADUS) announced September 14, 2026 a definitive agreement to acquire the personal care division of AccentCare, the Dallas-based home care and hospice company backed by Advent International, for approximately $275 million in cash, funded through Addus’s revolving credit facility and cash on hand. The deal covers AccentCare’s personal care operations outside New York across 10 states, Texas, Illinois, California, Arizona, Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington, serving an average daily census of about 13,700 customers, and excludes AccentCare’s separate hospice and home health businesses; Addus expects the operations to add roughly $280 million in annualized revenue, a 19 percent increase to its existing base. Addus Chairman and Chief Executive Officer Dirk Allison said the deal “directly aligns with our strategic growth initiatives” and is expected to be accretive to financial results, while AccentCare Chief Executive Officer Laura Tortorella called Addus “the ideal home for our personal care operations.” The deal lands the same week PitchBook data reported by Advisory.com showed overall healthcare private equity deal volume tracking 26.5 percent below 2025 and on pace for roughly 674 deals this year, the lowest annualized count PitchBook has recorded since 2017, with physician practice management deals falling especially fast amid regulatory scrutiny; Addus’s move shows strategic, publicly traded acquirers stepping into space PE sponsors are pulling back from, at least in personal care. Confidence: High on the deal terms, drawn from the companies’ own announcement. Medium on the PE-pullback framing, drawn from a single secondary analyst report rather than this run’s own deal-count review. Sources: Addus HomeCare Announces a Definitive Agreement to Acquire Personal Care Division of AccentCare, StockTitan, Addus To Acquire AccentCare’s Personal Care Division For $275M, Home Health Care News, Around the Nation: Private Equity’s Healthcare Pullback, Advisory.com.

A 344-bed Montgomery, Alabama trauma center just proved that a governor’s grant and a four-year insurance contract can pull a hospital back from the brink, one day before the bankruptcy court makes it official. Jackson Hospital announced September 14, 2026 that it has emerged from Chapter 11 bankruptcy protection, with one final status conference scheduled in bankruptcy court for September 15; the hospital’s path out relied on a four-year reimbursement-rate agreement with Blue Cross Blue Shield of Alabama signed in August, plus 40 million dollars in state capital-expense funding promised by Governor Kay Ivey and roughly 15 million dollars over three years in combined City of Montgomery and Montgomery County support, on top of 15 million dollars the city and 10 million dollars the county had already provided. Chief Executive Officer John Quinlivan said the BCBS deal “does not give us everything we felt we needed” but should let the hospital “successfully recruit physicians” and rehire staff lost during the bankruptcy; Blue Cross Blue Shield of Alabama said its “focus has remained on supporting our members and the community,” while Ivey called the hospital “reborn today stronger and ever more committed to delivering trusted medical care.” Confidence: Medium-High. This run relied on local television and Alabama news outlets’ direct reporting on the hospital’s and governor’s own statements rather than the bankruptcy court filing itself. Sources: Jackson Hospital reports it has emerged from bankruptcy, WSFA, Jackson Hospital signs deal with Blue Cross to stave off closure and emerge from bankruptcy, Alabama Daily News.

Sanofi just handed 20 of its older drugs and three factories to a smaller German company in exchange for a chunk of that company itself, the clearest sign yet of how the French drugmaker’s new leadership wants to run the business. Sanofi and Cheplapharm Arzneimittel announced September 14, 2026 a strategic partnership under which Cheplapharm takes over 20 of Sanofi’s mature medicines, including blood thinner Lovenox and Clexane (enoxaparin) outside the United States, along with three manufacturing sites, in Csanyikvolgy, Hungary, about 400 employees; Jurong, Singapore, about 100 employees; and Ploermel, France, about 65 employees; in return Sanofi receives a 26.4 percent equity stake in Cheplapharm, building on a commercial relationship the two companies started in 2014. The commercial transfer of the medicine portfolio is set to begin in the first quarter of 2027, with the full transaction expected to close by the third quarter of 2027, and Sanofi said the deal will not affect its 2026 financial guidance. Confidence: High. This run reviewed Sanofi’s own press release directly. Sources: Sanofi and Cheplapharm to create new strategic partnership in mature medicines, Sanofi.

LifeStance Health told investors this week that its mental health clinics are growing faster and more profitably than a year ago, numbers that matter beyond one company because behavioral health has been one of the few corners of provider economics still expanding while hospitals cut guidance elsewhere. At the Jefferies Healthcare Services and Technology Conference September 15, 2026, LifeStance Health Group executives said second-quarter revenue grew 26 percent year over year and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) grew 94 percent, prompting the company to raise full-year guidance by 45 million dollars in revenue for the quarter and 70 million dollars cumulatively for the year; the company now runs more than 575 physical centers and 8,500 clinicians treating more than one million patients a year across roughly half of the top 150 US markets, against a core therapy market it estimates at more than 50 billion dollars where it holds low single-digit penetration. Management said 2026 margins should expand more than 200 basis points versus 2025, targeting mid-30 percent center-level margins and a mid-teens adjusted EBITDA margin by 2028, with specialty service lines including transcranial magnetic stimulation and Spravato clinics growing revenue from 50 million dollars in 2024 to a projected 70 million dollars in 2025. Confidence: Medium-High. This run relied on a trade-press transcript of executives’ own conference remarks rather than the company’s own transcript or an 8-K filing. Sources: LifeStance Health Group at Jefferies Conference: growth stays strong, Investing.com.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
AccentCare’s personal care division (outside New York)	Addus HomeCare Corporation	Home care, personal care services	Approximately $275 million cash; announced September 14, 2026	StockTitan
20 mature medicines and 3 manufacturing sites (Sanofi)	Cheplapharm Arzneimittel (Sanofi receives 26.4% equity stake in Cheplapharm)	Pharmaceutical manufacturing, mature medicines	Undisclosed cash terms; 26.4% equity stake; announced September 14, 2026	Sanofi
TMG Global	Artisight (Nvidia-backed)	Smart hospital infrastructure, deployment engineering	Undisclosed; announced September 14, 2026	HIT Consultant
Hospital campus (60-bed hospital, 99-bed skilled nursing facility, medical office building), Marshall, Missouri	Strawberry Fields REIT	Healthcare real estate	Undisclosed; added to existing Master Lease with American Medical Administrators; announced September 15, 2026	Strawberry Fields REIT, GlobeNewswire

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours; the MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in fact discovery. A frontier check on healthcare cybersecurity and ransomware, a Ledger branch last touched August 1, found only aggregate 2026 statistics roundups rather than a new dated breach disclosure or business-impact story inside this run’s window; worth rechecking directly against HealthcareInfoSecurity next run. Norman Regional Health System’s roughly 40 million dollar interim bond financing, covered in this newsletter September 6 and September 11, was expected to close by September 15 per bond documents reviewed by Bond Buyer, but no source had confirmed an actual closing as of this run; we will report the outcome once confirmed rather than assume it.